B
iogen Inc. is relocating its global headquarters to Kendall Common in Cambridge, Massachusetts, as part of a multi-year consolidation plan. The new facility will integrate research and development teams with commercial organizations into a single innovation hub.

    Scheduled to open in 2028, Biogen's 50th anniversary year, the state-of-the-art building will commemorate five decades of scientific discovery and innovative treatments. "This marks a new chapter for Biogen in Kendall Square," said Christopher A. Viehbacher, President and CEO. "Our new space will foster collaboration with leading scientists, partners, and talent."

    Massachusetts Governor Maura Healey praised the move as an example of the state's continued growth in the life sciences sector. MIT President Sally Kornbluth noted that Biogen's decision to intensify its presence in Kendall Square promises great things for the ecosystem.

    Biogen has signed a 15-year lease for approximately 580,000 square feet of office and research space as part of the Kendall Common development project. The company plans to be the sole corporate tenant, allowing it to optimize its real estate footprint and create a purpose-built innovation hub with modern amenities and sustainable design elements.

    The new facility will also house the Biogen CoLab, a community laboratory and collaborative space where scientists, nonprofits, schools, and universities come together to promote careers in life science and healthcare. This marks a significant milestone for Biogen, which has been a foundational presence in the Massachusetts life science ecosystem since the early 1980s.

    MassBio CEO Kendalle Burlin O'Connell hailed Biogen's decision as a testament to the state's dominance in biotechnology and its commitment to collaboration, talent, and institutions.